Multiple Endocrine Adenomas — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for multiple endocrine adenomas. 1 active patents protecting 1 drugs from 1+ originators. First major cliff: 2026. Daily refresh.

1
Approved drugs
1
Active US patents
73/100
Avg vulnerability
—
Annual revenue covered

Originators in Multiple Endocrine Adenomas

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Pfizer 1 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating multiple endocrine adenomas. Each bar = one year. Y-axis scaled to peak year (1 patents).

1
26

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Pantoprazole Sodium
Pantoprazole Sodium
 Pfizer 1 73 — 2026-12-07

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
7544370 Pantoprazole Sodium other 80 2026-12-07

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
7544370 Pantoprazole Sodium other 80 2026-12-07

Related